Join Binding Site at ASH 2025: Transforming Multiple Myeloma Diagnostics with IBMS Technology
About ASH
This December, the Binding Site team will join leading innovators, researchers, and clinicians from around the world at American Society of Hematology (ASH) 2025.
With hundreds of sessions and thousands of abstracts, the ASH annual meeting is the largest hematology conference where the latest clinical advances from around the world are shared.
Why do we attend ASH?
At the Binding Site, part of Thermo Fisher Scientific, we are committed to improving patient lives through innovation. Attending ASH enables us to stay up to date with the latest research in Multiple Myeloma and related disorders, and share key information about our portfolio with like-minded experts.
Our recent contribution to Myeloma diagnostics
We recently announced in this press release that Binding Site has received 510(k) clearance for the EXENT® System to aid in the diagnosis of Multiple Myeloma.
Our team will be at ASH to answer any questions you may have on our innovative automated mass spectrometry solution.
Talk to us about
EXENT System
Multiple Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)
Meet the team
Nuno Barbosa
"As the EXENT Mass Spectrometry Global Scientific Affairs lead, my team and I partner with labs and clinicians worldwide to implement mass spectrometry for better patient care in monoclonal gammopathies. Our focus includes guideline compliance, education and research."
Languages spoken: English, Portuguese & Spanish
Rachel Carrington
"As a Global Scientific Marketing Liaison, I focus on driving education, awareness, and clinical adoption of the EXENT System. I am passionate about transforming complex scientific insights into impactful communication that empowers clinicians and laboratories worldwide to advance medical diagnostics."
Languages spoken: English
Florencia Delgado
"In my role leading Scientific Affairs across Latin America, I partner with labs and clinicians to help implement smart diagnostic solutions for better care of patients with monoclonal gammopathies. Patient-focused initiatives, quality, and guideline compliance are key drivers of my daily goals."
Languages spoken: English, Portuguese & Spanish
James Last
"As the Field Medical Science Liaison Leader, my focus is to engage with clinicians and laboratorians to discuss the latest developments in the field of monoclonal gammopathies, educate on the utility of Binding Site technologies and to explore novel areas of research using Binding Site products. Using these experiences allows me to help develop educational strategies and share best practices with the global Field MSL team, in order to deliver patient-focussed, guideline-compliant, sensitive and accurate clinical diagnostics."
Languages spoken: English
Craig Nowell
"In my role as a UK based field MSL I work with National Health Service (NHS) hospitals to support adoption of optimised laboratory testing algorithms for the diagnosis and monitoring of monoclonal gammopathies and immune system disorders and collaborate extensively with haematologists, immunologists and laboratory professionals. I also provide education to a variety of other clinical specialities to raise awareness of these disorders and to inform on the latest testing recommendations."
Languages spoken: English
Nick Paciaroni
"As an EXENT MSL, I collaborate with key opinion leaders in the field of hematology to help drive the sustained clinical adoption of the EXENT System for assessing monoclonal gammopathies. One of my main objectives is to educate laboratorians and clinicians about the added benefits of mass spectrometry testing to provide the best care for their patients."
Languages spoken: English
Jill Pauli
"In my role overseeing Scientific Affairs across North America, I collaborate with clinicians, researchers, and laboratory leaders to help enable scientific discovery and optimize care pathways for patients with plasma cell disorders. Our goal is to drive progress in myeloma care through precise, patient-centered, and guideline-informed diagnostics."
Languages spoken: English
Sandro Trova
"As a Global Scientific Marketing Liaison, I bridge science and communication with a passion for transforming complex diagnostic insights into clear, engaging educational content. My goal is to support clinicians and laboratory professionals, advocating for early diagnosis and informed patient monitoring."
Languages spoken: English & Italian
Bhrugu Yagnik
"As an MSL, I partner with clinicians and laboratory leaders to translate plasma cell disorder diagnostics into real-world hematology workflows - empowering healthcare teams to detect, monitor and manage blood cancer patients with greater precision and confidence."
Languages spoken: English, Gujarati & Hindi
Resources
Case study: New perspectives on monoclonal proteins
*The EXENT® System combines EXENT® Analyser with the Immunoglobulin Isotypes (GAM) for the EXENT® Analyser.
EXENT is a registered trademarks of The Binding Site Group Ltd (Birmingham, UK) in certain countries
© 2025 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific or its subsidiaries.
Product availability is subject to country specific regulatory requirements.
Contact your local representative for availability in your country.